2386 related articles for article (PubMed ID: 26765643)
1. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
2. Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study.
Turpie AGG; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Ageno W
Thromb Res; 2017 Jul; 155():23-27. PubMed ID: 28477534
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.
Mantovani LG; Haas S; Kreutz R; Folkerts K; Gebel M; Monje D; Schneider J; van Eickels M; Sahin K; Zell E; Ageno W; Turpie AGG
Eur J Intern Med; 2019 Mar; 61():29-33. PubMed ID: 30342973
[TBL] [Abstract][Full Text] [Related]
4. XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
Kreutz R; Mantovani LG; Haas S; Monje D; Schneider J; Bugge JP; Gebel M; Tamm M; Ageno W; Turpie AGG
Thromb Res; 2019 Apr; 176():125-132. PubMed ID: 30825694
[TBL] [Abstract][Full Text] [Related]
5. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
[TBL] [Abstract][Full Text] [Related]
6. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
[TBL] [Abstract][Full Text] [Related]
9. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
11. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D;
Lancet Haematol; 2019 Oct; 6(10):e500-e509. PubMed ID: 31420317
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
Prandoni P
Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
[TBL] [Abstract][Full Text] [Related]
13. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
14. XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis.
Ageno W; Mantovani LG; Haas S; Kreutz R; Haupt V; Schneider J; Turpie AG
Thromb J; 2014; 12():16. PubMed ID: 25093014
[TBL] [Abstract][Full Text] [Related]
15. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.
Wang X; Ma Y; Hui X; Li M; Li J; Tian J; Wang Q; Yan P; Li J; Xie P; Yang K; Yao L
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD010956. PubMed ID: 37058421
[TBL] [Abstract][Full Text] [Related]
16. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
; Büller HR; Prins MH; Lensin AW; Decousus H; Jacobson BF; Minar E; Chlumsky J; Verhamme P; Wells P; Agnelli G; Cohen A; Berkowitz SD; Bounameaux H; Davidson BL; Misselwitz F; Gallus AS; Raskob GE; Schellong S; Segers A
N Engl J Med; 2012 Apr; 366(14):1287-97. PubMed ID: 22449293
[TBL] [Abstract][Full Text] [Related]
17. The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
Akwaa F; Spyropoulos AC
Curr Med Res Opin; 2014 Nov; 30(11):2179-90. PubMed ID: 25105309
[TBL] [Abstract][Full Text] [Related]
18. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Robertson L; Kesteven P; McCaslin JE
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010957. PubMed ID: 26636644
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies.
Haas S; Mantovani LG; Kreutz R; Monje D; Schneider J; Zell ER; Tamm M; Gebel M; Bugge JP; Ageno W; Turpie AGG
Res Pract Thromb Haemost; 2021 Mar; 5(3):426-438. PubMed ID: 33870028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
